The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
Level 5 - mechanism / opinion, no new human data
Narrative literature review synthesizing 6 previously published clinical trials
PubMed 37940101 · doi:10.1016/j.japh.2023.10.037
What was done
Authors conducted a literature review across PubMed and Google Scholar using generic search terms for GLP-1 receptor agonists, tirzepatide, and hormonal contraceptives. The review evaluated clinical trial data regarding the comparative impact of incretin-based therapies on the bioavailability and pharmacokinetics of oral contraceptives. A total of six clinical trials were selected for synthesis.
What was found
The abstract does not provide exact numerical pharmacokinetic values. It reports that the single included trial evaluating tirzepatide showed statistically significant reductions in area under the plasma concentration-time curve (AUC), peak concentration (Cmax), and time to maximum concentration (Tmax) of oral hormonal contraceptives when co-administered. In contrast, the five trials evaluating GLP-1 receptor agonists demonstrated no statistically or clinically significant impact on oral hormonal contraceptive bioavailability.
Why it matters
Tirzepatide's pronounced delay in gastric emptying upon initiation impairs oral contraceptive absorption in a manner not observed with standard GLP-1 receptor agonists. Clinicians must be aware of this drug interaction to counsel patients on appropriate non-oral or barrier contraceptive methods.
Limits
The review included only one trial evaluating tirzepatide. The abstract reports pharmacokinetic metrics without numerical values and does not measure actual clinical endpoints, such as unintended pregnancy rates.
Cited by
- context GLP-1 receptor agonist medications interfere with the absorption of hormonal contraception.